Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 16
1987 53
1988 70
1989 81
1990 120
1991 147
1992 171
1993 148
1994 195
1995 281
1996 237
1997 223
1998 220
1999 237
2000 218
2001 222
2002 219
2003 179
2004 215
2005 315
2006 226
2007 175
2008 165
2009 190
2010 190
2011 176
2012 179
2013 139
2014 156
2015 165
2016 144
2017 130
2018 127
2019 75
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

5,524 results
Results by year
Filters applied: . Clear all
Page 1
Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, et al. Int J Clin Pharmacol Ther 2015 - Review. PMID 26329348
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflux disease (GERD). ...These results revealed a significant difference between esomeprazole vs. omeprazole (RR=1.06, 95% CI [1.01, 1.10], I2=72%, p=0.01) by subgroup according to dosage by random effects model, and a significant difference between esomeprazole 40 mg vs. omeprazole 20 mg (RR=1.07, 95% CI [1.004, 1.14], I2=78%, p=0.04) based on healing rate as determined by endoscopy, using a random effects model. ...
This study aims to evaluate the effectiveness and tolerability of esomeprazole and omeprazole in patients with gastroesophageal reflu …
Omeprazole: pharmacology, pharmacokinetics and interactions.
Oosterhuis B and Jonkman JH. Digestion 1989 - Review. PMID 2691315
Omeprazole may influence the pharmacokinetics of concurrently administered drugs by an inhibition of their oxidative metabolism. ...For every new combination of omeprazole with a drug that has a critical therapeutic range the consequences of a possible interaction should be studied....
Omeprazole may influence the pharmacokinetics of concurrently administered drugs by an inhibition of their oxidative metabolism. ...F
Association Between Proton Pump Inhibitors and Microscopic Colitis
Law EH, et al. Ann Pharmacother 2017 - Review. PMID 27733667
DATA SOURCES: We systematically searched EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts, and Google Scholar using the terms proton-pump inhibitors (omeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, or esomeprazole), microscopic colitis, collagenous colitis, and lymphocytic colitis. ...
DATA SOURCES: We systematically searched EMBASE, MEDLINE, Cochrane Database of Systematic Reviews, International Pharmaceutical Abstracts, a …
Clinical pharmacology of omeprazole.
Howden CW. Clin Pharmacokinet 1991 - Review. PMID 2029801
Omeprazole is a specific inhibitor of H+,K(+)-ATPase or 'proton pump' in parietal cells. This enzyme is responsible for the final step in the process of acid secretion; omeprazole blocks acid secretion in response to all stimuli. ...Omeprazole causes a dose-dependent increase in gastrin levels. Omeprazole must be protected from intragastric acid when given orally, and is therefore administered as encapsulated enteric-coated granules. ...
Omeprazole is a specific inhibitor of H+,K(+)-ATPase or 'proton pump' in parietal cells. This enzyme is responsible for the final ste
Comparative Study of Alginate and Omeprazole in Symptomatic Treatment of Non-erosive Gastroesophageal Reflux Disease.
Saifullah AM, et al. Mymensingh Med J 2018. PMID 30487493
Among them, 30 subjects were assigned to the omeprazole group (Group I) and 30 subjects to the alginate group (Group II). Omeprazole 20mg enteric coated capsule daily and alginate 10ml three times daily were administered 14 days in this study. ...Therapeutic efficacy and safety profiles of alginate were comparable to omeprazole after two weeks treatment in NERD subjects. ...
Among them, 30 subjects were assigned to the omeprazole group (Group I) and 30 subjects to the alginate group (Group II). Omeprazo
Esomeprazole
Spencer CM and Faulds D. Drugs 2000 - Review. PMID 10983736
Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer. ...Esomeprazole-based triple therapy for 7 days was as effective for eradication of Helicobacter pylori as longer omeprazole-based therapy in 2 randomised double-blind trials including about 450 patients each. ...
Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single …
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide.
Bækdal TA, et al. Expert Opin Drug Metab Toxicol 2018 - Clinical Trial. PMID 29897249
RESEARCH DESIGN AND METHODS: A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral semaglutide with omeprazole (40 mg once-daily) in 54 healthy subjects. ...Gastric pH was higher with oral semaglutide and omeprazole versus oral semaglutide alone. Adverse events were mild or moderate and, most commonly, gastrointestinal disorders. ...
RESEARCH DESIGN AND METHODS: A single-center, randomized, open-label, parallel-group trial investigated pharmacokinetic interactions of oral …
Prevalence of Gastroesophageal Reflux in Cats During Anesthesia and Effect of Omeprazole on Gastric pH.
Garcia RS, et al. J Vet Intern Med 2017 - Clinical Trial. PMID 28425145 Free PMC article.
Cats were randomized to receive 2 PO doses of omeprazole (1.45-2.20 mg/kg) or an empty gelatin capsule placebo 18-24 hours and 4 hours before anesthetic induction. ...Omeprazole administration was not associated with a significant increase in serum gastrin concentration (P = .616). Nine of 27 cats (33.3%) had ≥1 episode of GER during anesthesia. ...
Cats were randomized to receive 2 PO doses of omeprazole (1.45-2.20 mg/kg) or an empty gelatin capsule placebo 18-24 hours and 4 hour …
Omeprazole.
Langman MJ. Aliment Pharmacol Ther 1991 - Review. PMID 1777546
Omeprazole is a potent and effective antisecretory drug. Benefits in gastric and duodenal ulceration nevertheless seem marginal because standard treatments are very effective. ...
Omeprazole is a potent and effective antisecretory drug. Benefits in gastric and duodenal ulceration nevertheless seem marginal becau
5,524 results
Jump to page
Feedback